Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT: NCT05451771 · ACTIVE_NOT_RECRUITING

NCT IDNCT05451771
StatusACTIVE_NOT_RECRUITING
Start Date2022-10-26
Completion2027-09
SponsorColumbia University (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.

Frequently Asked Questions

What is Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis?

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis is a clinical trial registered under NCT05451771. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05451771?

The current status of NCT05451771 (Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis) is: ACTIVE_NOT_RECRUITING.

When did Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis start?

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis started on 2022-10-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑